Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration

Dow Jones01-30 21:39

By Colin Kellaher

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

Kyowa Kirin on Friday said the move is due to a strategic portfolio prioritization by Amgen, adding that it will regain control of the global program for the drug candidate, rocatinlimab, including regulatory filings and future commercialization.

Amgen in 2021 made an upfront payment of $400 million to Kyowa Kirin as part of an agreement to jointly develop and commercialize rocatinlimab for atopic dermatitis, with potential in other autoimmune diseases.

Kyowa Kirin, which discovered rocatinlimab, said it remains committed to developing the drug, currently in Phase 3 studies, and that it plans to file for regulatory approval in the U.S. later this year.

Amgen will continue to manufacture rocatinlimab, Kyowa Kirin said.

Thousand Oaks, Calif., biotechnology company Amgen and Japan-based specialty pharmaceutical company have been working together since 1984.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 30, 2026 08:39 ET (13:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607046857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607046857","market":"sg","top_or_hot":-1,"title":"Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis. \n</p>\n<p>\n  Kyowa Kirin on Friday said the move is due to a strategic portfolio prioritization by Amgen, adding that it will regain control of the global program for the drug candidate, rocatinlimab, including regulatory filings and future commercialization. \n</p>\n<p>\n  Amgen in 2021 made an upfront payment of $400 million to Kyowa Kirin as part of an agreement to jointly develop and commercialize rocatinlimab for atopic dermatitis, with potential in other autoimmune diseases. \n</p>\n<p>\n  Kyowa Kirin, which discovered rocatinlimab, said it remains committed to developing the drug, currently in Phase 3 studies, and that it plans to file for regulatory approval in the U.S. later this year. \n</p>\n<p>\n  Amgen will continue to manufacture rocatinlimab, Kyowa Kirin said. \n</p>\n<p>\n  Thousand Oaks, Calif., biotechnology company Amgen and Japan-based specialty pharmaceutical company have been working together since 1984. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 30, 2026 08:39 ET (13:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-30 21:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis. \n</p>\n<p>\n  Kyowa Kirin on Friday said the move is due to a strategic portfolio prioritization by Amgen, adding that it will regain control of the global program for the drug candidate, rocatinlimab, including regulatory filings and future commercialization. \n</p>\n<p>\n  Amgen in 2021 made an upfront payment of $400 million to Kyowa Kirin as part of an agreement to jointly develop and commercialize rocatinlimab for atopic dermatitis, with potential in other autoimmune diseases. \n</p>\n<p>\n  Kyowa Kirin, which discovered rocatinlimab, said it remains committed to developing the drug, currently in Phase 3 studies, and that it plans to file for regulatory approval in the U.S. later this year. \n</p>\n<p>\n  Amgen will continue to manufacture rocatinlimab, Kyowa Kirin said. \n</p>\n<p>\n  Thousand Oaks, Calif., biotechnology company Amgen and Japan-based specialty pharmaceutical company have been working together since 1984. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 30, 2026 08:39 ET (13:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242646821.SGD","symbol_name":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2607046857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607046857","pubTimestamp":1769780340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.Kyowa Kirin on Friday said the move is due to a strategic portfolio prioritization by Amgen, adding that it will regain control of the global program for the drug candidate, rocatinlimab, including regulatory filings and future commercialization.Amgen in 2021 made an upfront payment of $400 million to Kyowa Kirin as part of an agreement to jointly develop and commercialize rocatinlimab for atopic dermatitis, with potential in other autoimmune diseases.Kyowa Kirin, which discovered rocatinlimab, said it remains committed to developing the drug, currently in Phase 3 studies, and that it plans to file for regulatory approval in the U.S. later this year.Amgen will continue to manufacture rocatinlimab, Kyowa Kirin said.Thousand Oaks, Calif., biotechnology company Amgen and Japan-based specialty pharmaceutical compan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4581":"高盛持仓","BK4599":"减肥药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4566":"资本集团","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","AMGN":"安进","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"安进与协和麒麟结束特应性皮炎药物合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis. \n\n\n  Kyowa Kirin on Friday said the move is due to a strategic portfolio prioritization by Amgen, adding that it will regain control of the global program for the drug candidate, rocatinlimab, including regulatory filings and future commercialization. \n\n\n  Amgen in 2021 made an upfront payment of $400 million to Kyowa Kirin as part of an agreement to jointly develop and commercialize rocatinlimab for atopic dermatitis, with potential in other autoimmune diseases. \n\n\n  Kyowa Kirin, which discovered rocatinlimab, said it remains committed to developing the drug, currently in Phase 3 studies, and that it plans to file for regulatory approval in the U.S. later this year. \n\n\n  Amgen will continue to manufacture rocatinlimab, Kyowa Kirin said. \n\n\n  Thousand Oaks, Calif., biotechnology company Amgen and Japan-based specialty pharmaceutical company have been working together since 1984. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 08:39 ET (13:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607046857","isCrawlerRequest":true}